Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, Inc. (Nasdaq: CDNA) launched AlloCare, a mobile app aimed at enhancing medication adherence and health management for transplant patients. The app will debut at the AlloCare Transplant Festival on September 26, 2020, designed to foster connections within the transplant community. The festival will feature notable personalities and over 25 transplant organizations, emphasizing CareDx's commitment to improving long-term outcomes through innovative patient engagement solutions. The app is now available for download in the Apple App Store.
CareDx, Inc. (CDNA) announced its participation in the 28th International Congress of The Transplantation Society (TTS) from September 13-16, 2020. The company will showcase its AlloSure and AlloSeq cfDNA tools through four virtual symposia and six poster presentations. Expert speakers will discuss topics like risk prediction in kidney transplantation and the use of dd-cfDNA as a biomarker. CareDx aims to support continuous education for the transplant community and emphasize innovations in transplant medicine.
CareDx, Inc. (NASDAQ: CDNA), a precision medicine leader, has appointed new senior executives in key areas: Digital Services, Laboratory Operations, Business Development, and Market Access. The appointments aim to enhance operational efficiency amidst rapid growth. Notable new hires include Kashif Rathore, Ryan Phan, Sean Grant, and Danielle Scelfo, each bringing extensive experience from leading companies. CEO Peter Maag emphasizes the need for robust leadership to navigate increasing operational complexities and advance CareDx's market strategies.
CareDx, a precision medicine company, announced that its Chairman and CEO, Peter Maag, will present at the AAKP and George Washington University summit on July 16-17, 2020. The event focuses on innovations in kidney disease, particularly the role of artificial intelligence in transplant care. CareDx aims to enhance patient care through its digital tools, AiTraC and AlloCare, which address information management challenges for transplant patients. The summit highlights the global interest in improving transplant outcomes through data-driven solutions.
CareDx, Inc. (Nasdaq: CDNA) announced the publication of a study in Kidney360 evaluating its AlloSure tool against another monitoring method for kidney transplant rejection. The study, involving 76 patients, indicated that AlloSure provides faster results, with 75% of results delivered at least one day earlier than its counterpart, demonstrating superior accuracy in clinical interpretation. This validation highlights AlloSure's effectiveness in addressing transplant-specific testing needs.
CareDx (Nasdaq: CDNA) announced the full exercise of underwriters' option to purchase an additional 585,937 shares at $32.00 per share, resulting in net proceeds of approximately $17.6 million. This follows a public offering of 3,906,250 shares, which closed on June 15, 2020. With the additional shares, CareDx has sold a total of 4,492,187 shares, generating total net proceeds of around $134.7 million after expenses. The offering was managed by Goldman Sachs & Co. LLC and Jefferies LLC, among others.
CareDx, Inc. (Nasdaq: CDNA) has successfully closed a public offering of 3,906,250 shares of common stock priced at $32.00 per share, generating net proceeds of approximately $117.1 million. The underwriters also have a 30-day option to purchase an additional 585,937 shares. These funds are earmarked for working capital and general corporate purposes. The offering was conducted under a shelf registration statement, effective since June 9, 2020. Goldman Sachs & Co. LLC and Jefferies LLC served as joint book-running managers.
CareDx, Inc. (Nasdaq: CDNA) has announced the pricing of a public offering of 3,906,250 shares at $32.00 per share, aiming for gross proceeds of $125 million. The offering includes a 30-day option for underwriters to purchase an additional 585,937 shares. Expected to close around June 15, 2020, proceeds will support working capital and corporate purposes. The offering is registered under Form S-3ASR with the SEC. Goldman Sachs & Co. LLC and Jefferies LLC are leading the offering.
CareDx, Inc. (Nasdaq: CDNA) announced plans for an underwritten public offering of up to $100 million in its common stock. The company may grant underwriters a 30-day option to purchase an additional $15 million in shares. Proceeds will be used for working capital and general corporate purposes. The offering is contingent on market conditions and is being managed by Goldman Sachs & Co. LLC and Jefferies LLC. The offering is registered under a previously filed shelf registration statement with the SEC, and a preliminary prospectus will be available shortly.
CareDx, Inc. (Nasdaq: CDNA) announced an update regarding its 2020 Annual Meeting of Stockholders, which will now take place in a virtual format only due to COVID-19 restrictions. The meeting is scheduled for June 17, 2020, at 10:00 a.m. Pacific Time, and will cover the same agenda as previously communicated. Stockholders can still vote prior to the meeting using previously issued proxy materials. Instructions for attending the virtual meeting are provided, requiring a control number for stockholders, while guests can join with just their name and email.